Castle Biosciences Licenses BAP1 Gene from Wash U. for Melanoma Metastasis Detection | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Castle Biosciences today announced it has licensed the BAP1 gene from Washington University in St. Louis for detecting metastasis in patients with melanoma.

The Friendswood, Texas-based firm has begun validation studies for use of the technology in both uveal melanoma, or ocular melanoma, and cutaneous melanoma and plans to incorporate the gene into its DecisionDx-UM assay. It also has an option for use of the gene for other cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.